Pilot Observational Study of an Integrative Cure Stay Program

Summary

This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program "Via Shalva" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.

Eligibility

Inclusion Criteria:

* Breast and gynecological cancer (including but not limited to ovarian, endometrial, cervical, vulvar and vaginal cancer) survivors, including recurrent disease
* Completed primary treatment (operation +/- radiation +/- chemotherapy)
* Age ≥ 18 years
* Ongoing or planned maintenance treatment scheduled for \> 3 months during study period is allowed (e.g. antihormonal therapy, Anti-Her2-antibodies, CDK4/6-inhibitors, Anti-VEGF-inhibitor, PARP-inhibitor, immune-checkpoint inhibitors etc.)
* Signed informed consent for participation of the trials
* Presence of a stoma is allowed
* Prior cancer is allowed
* Prior treatment - including chemotherapy - for a prior malignant tumor (including breast or gynecological cancer) is allowed
* Concomitant participation in an experimental therapeutic drug trial is allowed
* Use of other complementary methods (including mistletoe) is allowed
* Pregnancy is allowed.

Exclusion Criteria:

* Language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study
* Severe physical or psychiatric comorbidity that prevents a patient from participating in the study
* Patients incapable of giving consent

Conditions3

Browse More Trials